Non-erosive reflux disease: The real problem in gastro-oesophageal reflux disease

Digestive and Liver Disease

Volumn 33, Issue 7, 2001, Pages 523-527

  Quigley, E M M ^a   DiBaise, J K ^b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; OMEPRAZOLE; PEPSIN A; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSPEPSIA; ENDOSCOPIC SURGERY; ENDOSCOPY; EROSION; EXPOSURE; GASTROESOPHAGEAL REFLUX; HUMAN; META ANALYSIS; MUCOSA; NERVE INJURY; PATHOPHYSIOLOGY; PH; STOMACH ACID; STOMACH FUNDOPLICATION; VAGUS NERVE;

DYSPEPSIA; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; QUALITY OF LIFE;

EID: 0034777663     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(01)80100-6     Document Type: Article

References (61)

1. Epidemiology and natural history of gastroesophageal reflux disease
2. Endoscopy-negative acid reflux disease
3. Heartburn without esophagitis: Efficacy of omeprazole therapy and features determining therapeutic response
4. An evidence-based appraisal of reflux disease management: The Genval Workshop Report
5. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - A placebo-controlled randomized trial
6. The illness behavior of patients with gastroesophageal reflux disease with and without endoscopic esophagitis
7. The significance of intraepithelias eosinophils in the histologic diagnosis of gastroesophageal reflux
8. Diagnostic value of histology in non-erosive gastroesophageal reflux disease
9. Non-erosive reflux disease (NERD) - Current concepts and dilemmas
10. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - The "sensitive oesophagus"
11. Acid perception in gastro-oesophageal reflux disease is dependent on psychosocial factors
12. Functional esophageal disorders
13. Empirical trials in treatment of gastroesophageal reflux disease
14. Gastro-oesophageal reflux disease
15. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: Evidence for a spectrum of visceral sensitivity in GORD
16. Reflux related symptoms in patients with normal, esophageal exposure to acid
17. Differential effect of long-term esophageal acid exposure on mechano-sensitivity and chemo-sensitivity in humans
18. Dyspepsia and dyspepsia subgroups: A population-based study
19. Motility, heartburn and dyspepsia
20. An open-label comparison of omeprazole and cisapride in endoscopy-negative reflux disease
21. Electron microscopic changes in human oesophageal epithelium in oesophagitis
22. Morphologic alterations in early acid-induced epithelial injury of the rabbit esophagus
23. Dilated intracellular spaces: A morphological feature of acid reflux-damaged human esophageal epithelium
24. Natural history of gastro-oesophageal reflux disease without oesophagitis
25. Three-year follow-up of patients with gastroesophageal reflux disease
26. The natural history, prevalence and incidence of reflux oesophagitis
27. Predictive factors of the long-term outcome in gastro-oesophageal reflux disease: Six-year follow-up of 107 patients
28. Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux
29. Natural history of reflux oesophagitis: A 10-year follow-up of its effect on patient symptomatology and quality of life
30. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients
31. Disease progression in gastro-oesophageal reflux disease as determined by repeat oesophageal pH monitoring and endoscopy 3 to 4.5 years after diagnosis
32. Three- to 4.5-year prospective study of prognostic indicators in gastro-oesophageal reflux disease
33. Non-Erosive Reflux Disease (NERD); part of the spectrum of gastro-oesophageal reflux, a component of functional dyspepsia, or both?
34. Efficacy of omeprazole in functional dyspepsia: Double-blind, randomized, placebo-controlled trials (the Bond and Opera studies)
35. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal disease
36. Functional gastroduodenal disorders
37. Transient lower esophageal sphincter relaxation
38. Role of impaired gastric accommodation to a meal in functional dyspepsia
39. Motor function of the proximal stomach and visceral perception in gastro-oesophageal reflux disease
40. Motor and sensory function of the stomach in reflux disease and after laparoscopic. Nissen fundoplication
41. Treating the symptoms of gastroesophageal reflux disease: A double-blind comparison of omeprazole and cisapride
42. Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease
43. 2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy-negative reflux disease (Cochrane Review)
44. Efficacy of Omeprazole for the treatment of symptomatic acid reflux disease without esophagitis
45. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis
46. Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis
47. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole
48. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice
49. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis. The U.S. multicenter study
50. A comparison of the efficacy of omeprazole 20 mg once daily with ranitidine 150 mg bd in the relief of symptomatic gastro-oesophageal reflux in general practice
51. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans
52. A comparison of five maintenance therapies for reflux esophagitis
53. Quality of life and cost of therapy in reflux disease
54. Symptomatic gastro-oesophageal reflux disease: Double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study
55. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - A placebo-controlled randomized trial
56. Quality of life in patients with heartburn but without esophagitis: Effects of treatment with omeprazole
57. On-demand therapy for gastro-oesophageal reflux disease
58. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
59. Multivariate analysis of factors predicting outcome after laparoscopic fundoplication
60. Outcomes of laparoscopic antireflux procedures
61. Prospective study of the effect of laparoscopic hemifundoplication on motor and sensory function of the proximal stomach